HRP20210379T1 - Poboljšane formulacije - Google Patents
Poboljšane formulacije Download PDFInfo
- Publication number
- HRP20210379T1 HRP20210379T1 HRP20210379TT HRP20210379T HRP20210379T1 HR P20210379 T1 HRP20210379 T1 HR P20210379T1 HR P20210379T T HRP20210379T T HR P20210379TT HR P20210379 T HRP20210379 T HR P20210379T HR P20210379 T1 HRP20210379 T1 HR P20210379T1
- Authority
- HR
- Croatia
- Prior art keywords
- fluticasone propionate
- formoterol fumarate
- micrograms
- hfa
- suspension formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918150.4A GB0918150D0 (en) | 2009-10-16 | 2009-10-16 | Improved formulations |
| EP10768760.0A EP2488157B1 (en) | 2009-10-16 | 2010-10-15 | Improved formulations |
| PCT/EP2010/065569 WO2011045429A1 (en) | 2009-10-16 | 2010-10-15 | Improved formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210379T1 true HRP20210379T1 (hr) | 2021-04-16 |
Family
ID=41462451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210379TT HRP20210379T1 (hr) | 2009-10-16 | 2010-10-15 | Poboljšane formulacije |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20120263766A1 (OSRAM) |
| EP (2) | EP2488157B1 (OSRAM) |
| JP (2) | JP5818801B2 (OSRAM) |
| CN (1) | CN102573791B (OSRAM) |
| AU (1) | AU2010305695B2 (OSRAM) |
| BR (1) | BR112012008969B1 (OSRAM) |
| CA (1) | CA2776845C (OSRAM) |
| CL (1) | CL2012000948A1 (OSRAM) |
| CY (1) | CY1123918T1 (OSRAM) |
| DK (1) | DK2488157T3 (OSRAM) |
| ES (1) | ES2859629T3 (OSRAM) |
| GB (1) | GB0918150D0 (OSRAM) |
| HR (1) | HRP20210379T1 (OSRAM) |
| HU (1) | HUE054030T2 (OSRAM) |
| IL (2) | IL219162A0 (OSRAM) |
| LT (1) | LT2488157T (OSRAM) |
| MX (1) | MX372991B (OSRAM) |
| NZ (1) | NZ599900A (OSRAM) |
| PL (1) | PL2488157T3 (OSRAM) |
| PT (1) | PT2488157T (OSRAM) |
| RS (1) | RS61430B1 (OSRAM) |
| SI (1) | SI2488157T1 (OSRAM) |
| SM (1) | SMT202100150T1 (OSRAM) |
| WO (1) | WO2011045429A1 (OSRAM) |
| ZA (1) | ZA201202595B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| JP6335798B2 (ja) * | 2012-02-28 | 2018-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規噴射剤含有チオトロピウム製剤 |
| JP2015512929A (ja) * | 2012-04-11 | 2015-04-30 | シプラ・リミテッド | 医薬組成物 |
| GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| CN105963282B (zh) * | 2016-05-04 | 2019-04-19 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
| WO2018059390A1 (zh) * | 2016-09-29 | 2018-04-05 | 广东东阳光药业有限公司 | 药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| AU718263B2 (en) | 1995-04-14 | 2000-04-13 | Smithkline Beecham Corporation | Metered dose inhaler for salmeterol |
| AU710382B2 (en) | 1995-04-14 | 1999-09-16 | Glaxo Wellcome Inc. | Metered dose inhaler for albuterol |
| JPH101442A (ja) * | 1996-06-12 | 1998-01-06 | Taisho Pharmaceut Co Ltd | 鼻炎用点鼻薬 |
| CZ295460B6 (cs) * | 1997-03-20 | 2005-08-17 | Schering Corporation | Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| HRP20021025B1 (hr) * | 2000-05-22 | 2013-11-22 | Chiesi Farmaceutici S.P.A. | Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom |
| US20030207057A1 (en) | 2000-09-18 | 2003-11-06 | Britto Ignatius Loy | Metered dose inhaler can coated two or more times with fluorocarbon polymers |
| ATE320242T1 (de) * | 2000-10-09 | 2006-04-15 | 3M Innovative Properties Co | Medizinische aerosolzusammensetzung |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| GB0201400D0 (en) * | 2002-01-22 | 2002-03-13 | Glaxo Group Ltd | Novel apparatus and process |
| WO2004019985A1 (en) * | 2002-08-29 | 2004-03-11 | Cipla Ltd | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0327727D0 (en) * | 2003-11-28 | 2003-12-31 | Quadrant Drug Delivery Ltd | Viral microparticles |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
-
2009
- 2009-10-16 GB GBGB0918150.4A patent/GB0918150D0/en not_active Ceased
-
2010
- 2010-10-15 ES ES10768760T patent/ES2859629T3/es active Active
- 2010-10-15 US US13/502,097 patent/US20120263766A1/en not_active Abandoned
- 2010-10-15 SM SM20210150T patent/SMT202100150T1/it unknown
- 2010-10-15 AU AU2010305695A patent/AU2010305695B2/en active Active
- 2010-10-15 DK DK10768760.0T patent/DK2488157T3/da active
- 2010-10-15 EP EP10768760.0A patent/EP2488157B1/en active Active
- 2010-10-15 SI SI201032050T patent/SI2488157T1/sl unknown
- 2010-10-15 LT LTEP10768760.0T patent/LT2488157T/lt unknown
- 2010-10-15 CN CN201080046305.6A patent/CN102573791B/zh active Active
- 2010-10-15 MX MX2012004338A patent/MX372991B/es active IP Right Grant
- 2010-10-15 NZ NZ599900A patent/NZ599900A/en unknown
- 2010-10-15 PL PL10768760T patent/PL2488157T3/pl unknown
- 2010-10-15 BR BR112012008969-2A patent/BR112012008969B1/pt active IP Right Grant
- 2010-10-15 CA CA2776845A patent/CA2776845C/en active Active
- 2010-10-15 WO PCT/EP2010/065569 patent/WO2011045429A1/en not_active Ceased
- 2010-10-15 JP JP2012533648A patent/JP5818801B2/ja active Active
- 2010-10-15 HU HUE10768760A patent/HUE054030T2/hu unknown
- 2010-10-15 EP EP20213235.3A patent/EP3811928A1/en not_active Withdrawn
- 2010-10-15 HR HRP20210379TT patent/HRP20210379T1/hr unknown
- 2010-10-15 PT PT107687600T patent/PT2488157T/pt unknown
- 2010-10-15 RS RS20210159A patent/RS61430B1/sr unknown
-
2012
- 2012-04-11 ZA ZA2012/02595A patent/ZA201202595B/en unknown
- 2012-04-13 CL CL2012000948A patent/CL2012000948A1/es unknown
- 2012-04-15 IL IL219162A patent/IL219162A0/en unknown
-
2015
- 2015-09-29 JP JP2015191177A patent/JP2016040286A/ja active Pending
-
2017
- 2017-03-21 US US15/464,879 patent/US20180296468A2/en not_active Abandoned
-
2019
- 2019-09-15 IL IL26936919A patent/IL269369A/en unknown
-
2021
- 2021-03-05 CY CY20211100190T patent/CY1123918T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210379T1 (hr) | Poboljšane formulacije | |
| Hindle et al. | Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device | |
| JP2013507429A5 (OSRAM) | ||
| HRP20200260T1 (hr) | Pripravci, postupci i sustavi za respiratornu isporuku dva ili više aktivnih sredstava | |
| HRP20221432T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| Hindle et al. | Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model | |
| Pozzoli et al. | Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation | |
| WO2009112274A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| ME02342B (me) | Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom | |
| JP2012503668A5 (OSRAM) | ||
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| JP2020527377A5 (OSRAM) | ||
| JP2014530231A5 (OSRAM) | ||
| Chrystyn | Is total particle dose more important than particle distribution? | |
| HK1200343A1 (en) | An inhalable medicament comprising tiotropium | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| WO2008053250A3 (en) | Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser | |
| Pornputtapitak et al. | Nanocluster budesonide formulations enhance drug delivery through endotracheal tubes | |
| Bagherisadeghi et al. | Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| Titosky et al. | The effect of altitude on inhaler performance | |
| Chen et al. | The effect of active pharmaceutical ingredients on aerosol electrostatic charges from pressurized metered dose inhalers | |
| Takizawa | Recent development of drug delivery systems for the treatment of asthma and related disorders |